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ABSTRACT 
A simplified, rapid and inexpensive extraction procedure for the determinaticn of the antiarrhythmic 
drug disopyramide and its main mctabolitc mono-N-dcsalkylated disopyramidc in strum by high-pcrform- 
ante liquid chromatography has been developed. The analysis uses ullraviolct detection at 254 nm, and a 5 
jtm reversed-phase column with a mobile phase of water-tricthylaminc-acctonitrilc-PIG-B8 reagent. Sc- 
rum extraction is performed with dichloromethane and 1 &f sodium hydroxide. p-Chlorodisopyramide is 
used as internal standard. Recovery rates were 94.5% (SD. 5.7%) for disopyramide, 96.5% (S.D. 2.2%) 
for mono-N-desalkylatcd disopyramidc and 97.9% (S.D. 2.8%) for the internal standard. 
INTRODUCTION 
Disopyramide is a widely used antiarrhythmic drug with class Ia activity, ac- 
cording to the Vaughan and Williams classification [1,2]. In clinical trials it has 
been shown to be effective for treatment of atria1 fibrillation [3-S] and ventricular 
arrhythmias [4,6-l 11. Although successful treatment of arrhythmias may not be 
directly correlated with serum levels, determination of serum levels is helpful to 
check compliance, especially in out-patient treatment, when side-e-Sects occur, 
and to exclude sub-optimal dosing, especially in oral therapy; 
Serum concentrations of mono-N-desalkylated disopyramide (MND) reach cn. 
30% of the disopyramide serum concentration during long-term oral therapy [12] 
and are increased by enzyme induction or renal failure [12,13]. As MND is re- 
ported to have a lower antiarrhythmic activity but marked anticholirergic activ- 
ity [13], determination of MND seems to be useful, when anticholinergic side- 
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effects, such as reduced salivation, accommodation disturbances or prostation 
occur. 
The aim of the present study was to develop a rapid, inexpensive 




Disopyramide, MND and p-chlorodisopyramide were provided by Albert 
Roussel Pharma (Wiesbaden, Germany). Acetonitrile, hydrochloric acid, 
triethylamine, dichloromethane and sodium hydroxide were obtained from 
Merck (Darmstad;, Germany). !-Octanesulphonic acid (5 M, PIC-BS reagent) 
was purchased from Waters Assoc. (Eschborn, Germany). 
The high-performance liquid chromatographic (HPLC) system consisted of a 
Model 721 system controller, a data module Model 730, an HPLC pump, a WISP 
71 OB injector block anti a Lambda-Max Model 48 1 variable-wavelength detector 
(all from Waters Assoc..). 
A 2.0-ml volume of dichloromethane, 110 ml of serum, 100 ~1 of 1 M sodium 
hydroxide and 100 p.ri of the stock solution of the internal standard were in- 
troduced into a glass centrifuge tube, obtained from KBstner (Tubingen, Germa- 
ny). The tube was stoppered with a plastic stopper, obtained from Sarstedt 
(Ntimbrecht, Germany), vortex-mixed for 60 s and centrifuged at 3600 g for 10 
min. Subsequently the aqueous phase was discarded, and 1.0 ml of the dichloro- 
methane phase was transferred to a clean glass tube and evaporated to dryness at 
room temperature under nitrogen. The residue was dissolved in 500 ,ul of 0.01 M 
hydrochloric acid, and 200 ,~l were injected into the column. 
Standards 
The ktock standard solutions were prepared by dissolving 3 mg of disopyra- 
mide, 3 mg of MND and 3 mg of p-chlorodisopyramide each in 100 ml of 0.01 M 
hydrochloric acid. In this way stock standard solutions, containing 30 pg/ml of 
each substance, were obtained, which proved to be stable for at least two months 
at 4°C. A working standard solution was prepared by combining 100 ~1 of each 
stock standard solution with 700 ~1 of 0.01 A4 hydrochloric acid. This working 
standard solution contained disopyramide, MND and the internal standard p- 
chlorodisopyramide in concentrations of 3 /cg/ml each. . 
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Cetection wavelength 
To find the optimal detection wavelength, UV absorption spectral analysis was 
performed over a wavelength range of 200-500 nm with the stock standard solu- 
tions of disopyramide and MND. Both substances showed a maximum of ab- 
sorption at 2% nm. 
Chromatograpitic conditions 
The analysis was performed at room temperature using a Shandon ODS re- 
versed-phase column (125 mm x 4.6 mm I.D., particle size 5 pm). The mobile 
phase consisted of 70% A (974 ml of water, 25 ml of PIC-BS reagent and 1 ml of 
triethylamine) and 30% B (acetonitrile). The concentration of I-octanesulphonic 
acid in part A of the mobile phase was 0.0125 h$. The flow-rate was 1 .O ml/min. 
The column effluent was monitored at 254 nm, Itsing a detector or range of 0.02 
a.u.f.s. and a chart-speed of 0.5 cm/min. The injection volume ~2s 200 $. 
Louver limit of detectiolt 
The lower limit of detection was determined by diluting the working standard 
solution to concentrations of 1 .O, 0.5, 0.25,O. 1 and 0.05 pg/ml for disopyrLmide, 
MND and the internal standard. A signal-to-noise ratio of 3: 1 was set as the limit 
for detection of a peak. 
Recovery rntes 
Recovery rates were determined by comparing the peak areas of disopyramide, 
MND and the internal standard? obtained by analysing ten spiked serum samples 
(10G ~1 of each stock solution, added to 1 .O ml of normal pool serum), with peak 
areas obtained by direct injection of the standard working solution. 
The technical error was determined by injecting the same sample ten times. Ten 
peak areas were compared and given as percentage values. 
Limarity test 
The linear relationship of peak areas to substance concentrations was demon- 
strated by analysing five standard so!utions, containing concentrations of 6.00, 
3.00, 1.50, 0.75 and 0.375 pg/ml disopyramide, MND and the internal standard. 
Peak areas were plotted versus substance concentration< in orthogonal scaies and 
resulted in a linear curve. 
The same procedure was performed for spiked serum samples, containing simi- 
lar concentrations of disopyramide, MND and the internal standard. 
Quant#kntiorz 
Because a linear relationship between substance concentrations and peak areas 
was obtained, no daily calibration graph was necessary. Calculation was per- 
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formed by comparing peak arcas of the standard working solution (analysed 
before every serum sample) to peak areas of serum samples, obtained by the 
described extraction procedure. 
Blood was taken by venous puncture of a gubital vein, and serum was obtained 
by centrifugation at 900 g, avoiding haemolysis. Twenty-two serum samples from 
normal volunteers (twelve male, ten female) were pooled (normal pool). This 
drug-free no1 ma1 pool serum was used for blank chromatograms and for prepar- 
ing spiked serum samples for the linearity test and for the recovery rate. 
Eleven undiluted serum samples from patients treated with cardiovascular 
drugs, such as acetylsalicylic acid, heparin, phenprocoumone, nifedipine, diltia- 
zem, verapamil, nitrendipine, betaxolol, metoprolol, isosorbide mononitrate, fu- 
rosemidc, xipamide, spironolactone, hydrochlorothiazide, triamterene, allopuri- 
nol, bezciibrate, enalapril, captopril, digitoxin, metildigoxin, digoxin and 
diazepam, were analysed with the above described assay. 
Fifteen serum samples from fifteen patic-:ats (three female, twelve male) under- 
going chronic oral therapy (;lt least five days) with two 250-mg sustained-release 
tablets per day were analysed individually. Samples were taken as trough levels at 
8:00 a.m. before the morning dose was taken. None of the patients had signs of 
congestive heart failure or kidney or liver dysfunction. 
RESULTS 
-4 linear relationship between the concentration oft’-- a~~ suI~?ances and the peak 
areas for the standards, as well as for spiked serum samples, couId be demon- 
strated. The mean recovery rates were 94.5 f 5.7% for disopyramide (coefficient 
of variation, C.V. 6.030/b), 96.8 =t 2.2% for MND (C.V. 2.27%) and 97.9 f 
2.8% for the internal standard (C.V. 2.86%). 
The inter-assay C.V. (II = 10) were 6.0% for disopyramide and 2.3% for 
MND. The intra-assay C.V. (12 = 10) were 2.7% for disopyramide and 1.4% for 
MND. The technical error of the apparatus was less than 1% for disopyramide, 
MND and the internal standard. Disopyramide serum levels were 2.00 f 0.85 
/lg/ml and MND levels were 0.60 f 0.33 Gg/ml, in fifteen patients taking 270 f 
14 mg of disopyramide per square mctre of body surface orally (data given as 
mean f S.D.). 
None of the above-mentioned drugs showed interference with the determina- 
tion of discpyramide. There was no significant correlation either between dosage 
per body surface area or serum concentrations of disopyramide or MND in 
fifteen patients during chronic oral drug treatment. Serum concentrations of 
MND were 23.7% (S.D. 10.4”/b) of disopyramide serum concentrations. 
Typical chromatograms obtained from the analysis of a blank from the normal 























Fig. 1. Chromntogrnms of a blank of the normal pool (A), of a standard working solution (B) and of the 
serum of a patient receiving disopyramidc (C). 
peak area= 0,79d~cIHND)-O,lOO.r=0.9956 
peak area= O,SBb*cIdisl-0,062,r=0,999? 
peak area= 0,631 .c[is)-0,114,r=0.9999 
4 
l- 
Fig. 2. Linearity test for (A) disopyramidc. (Cl) MND and (0) the internal standard in the standard 
solution. c(MND) = concentration of MND; c(dis) = concentration of disopyramidc; c(is) = conccntra- 
tion of internal standard. 
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1 peak orea= 0,72l*ctMNDI-0,068. r q 0.9995 
peok Oreo= 0,58l*ctdlsI -0,044, r =0,9995 
peak Oreo= 0,68L*clisl-0,099,r=0.9994 
4- 
I I 
1 2 3 4 5 6 yglml 
Fig. 3. Linearity test for (A) disopyramidc. (0) MND and (a) the internal standard in n spiked serum 
sumplc. c(MND) = conccntrntion of MND; c(dis) = conccn;ration of disopyramidc; c(k) = conccntra- 
tion of intcrmrl standard. 
are shown in Fig. 1. Linearity tests on the standard solution and on a spiked 
serum sample are demonstrated in Figs. 2 and 3. 
DISCUSSION 
Gas chromatographic methods have proved to be highly.specific and sensitive 
for measuring serum levels of disapyramide [14-I 91, but have the disadvantage 
that the samples have to be derivatized and therefore the analyses are more 
time-consuming. 
Immunological methods for measuring disopyramide levels with monocIona1 
antibodies have been developed [20-231 but quantification of MND is not pos- 
sible. 
A variety of HPLC methods with UV detection for determination of disopyra- 
mide have been published [16,24-33]. Some give essenriaiiy lower analytical re- 
covery rates for disopyramide or its main metabolite MND [26,29,30]. Without 
an internal standardization some methods need a time-consuming calibration 
graph to be prepared before every analysis [27,28]. Ilett et al. [16] used organic 
liquid extraction with dichloromethane, but quantitative determination of MND 
and analytical recovery rates were not described in this publication. The method 
published by Angelo ei crl. 1241 gives excellent recovery rates for disopyramide and 
MND, but their use of dimethyl ether for extraction has several disadvantages 
(working with an inflammable, explosive and narcotic substance in closed 
rooms). Methods published by Radwan ei ai. [31], Sweezy and Ponzo [33] and 
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Broussard and Frings [25] do not aliow determination of MND. Wang et al. [33] 
used a silica gel column and an aqueous mobile phase, consisting of dibasic 
ammonium phosphate. This method gives high recovery rates for disopyramide 
and MND, btit is rather expensive, because HzS04, the solvent for probe in- 
jection, quickly destroys the analytical column, despite the presence of a guard 
co!umn . 
The method described in this paper for determination of disopyramide and its 
main metabolite MND in serum is easy to handle, rapid to perform and in- 
expensive. Nearly complete analytical recovery of disopyramide and MND is 
obtained. The range of detection (0. I-6.0 irg/ml) is sufficient for monitoring sub- 
therapeutic levels (e.g. single-dose studies) as well as toxic levels. 
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